 |
|
|
|
|
|
 Title: |
US6471967:
Recombinant intracellular pathogen vaccines and methods for use[En]
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Horwitz, Marcus A.; Los Angeles, CA
Harth, Gunter; Los Angeles, CA
|
| Assignee: |
The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
2002-10-29
/ 2000-04-17
|
| Application Number: |
US2000000550468
|
| IPC Code: |
Advanced:
A61K 39/02;
A61K 39/04;
A61K 39/108;
A61K 39/116;
A61K 39/118;
A61P 31/06;
A61P 37/04;
C07K 14/35;
A61K 38/00;
Core:
A61P 31/00;
A61P 37/00;
C07K 14/195;
more...
IPC-7:
A61K 39/00;
A61K 39/02;
A61K 39/04;
A61K 39/38;
C12N 15/00;
|
| ECLA Code: |
A61K39/04;
|
| U.S. Class: |
424/248.1;
424/009.1;
424/009.2;
424/184.1;
424/185.1;
424/192.1;
424/200.1;
424/234.1;
435/320.1;
|
| Field of Search: |
424/9.1,9.2,184.1,185.1,192.1,200.1,234.1,248.1
435/320.1
|
| Government Interest: |
REFERENCE TO GOVERNMENT
This invention was made with Government support under Grant No. AI31338 awarded by the Department of Health and Human Services. The Government has certain rights in this invention.
|
| Priority Number: |
| 2000-04-17 |
US2000000550468 |
|
| Abstract: |
Vaccines and immunotherapeutics for preventing intracellular pathogen diseases in mammals are provided that consist of recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens. Exemplary vaccines and immunotherapeutics include attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. These exemplary vaccines are shown to produce surprisingly potent protective immune responses in mammals that surpass those of any previously known anti-mycobacterium vaccine. More specifically, a recombinant BCG expressing the 30 kDa major extracellular non-fusion protein of Mycobacterium tuberculosis is provided. Additionally, methods for preventing and treating diseases caused by intracellular pathogens are provided. The methods of treating and preventing intracellular pathogen diseases utilize the described surprisingly efficacious vaccines and immunotherapeutics.
[En]
|
| Attorney, Agent or Firm: |
Oppenheimer Wolff & Donnelly LLP ;
Cullman, Louis C. ;
|
| Primary / Asst. Examiners: |
Swartz, Rodney P;
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
| Designated Country: |
AE AG AL AM AP AT AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EA EE EP ES FI GB GD GE GH GM HR HU ID IL IN IS
|
| Family: |
Show 18 known family members
|
First Claim:
Show all 6 claims |
We claim:
1. An immunogenic composition comprising:
- a recombinant Bacille Calmette-Guerin (BCG) having an extrachromosomal nucleic acid sequence comprising a gene encoding for a Mycobacteria tuberculosis 30 kDa major extracellular protein, wherein said Mycobacteria tuberculosis 30 kDa major extracellular protein is over expressed and secreted.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 2 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
|
| Other Abstract Info: |
CHEMABS 135(23)330480K
DERABS C2002-034322
|
| Other References: |
Lee et al., T-Cell Epitope Mapping of the Three Most Abundant Extracellular Proteins of Mycobacterium tuberculosis in Outbred Guinea Pigs, Infection and Immunity, May 1999, p. 2665-2670, vol. 67, No. 5.
(6 pages)
Cited by 2 patents
[ISI abstract]
Horwitz et al., Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model, PNAS, Dec. 5, 2000, vol. 97, No. 25.
Ohara et al.. Inhibition of Multiplication of Mycobacterium Laprae in Mouse Foot Pads by Recombinant Bacillus Catmette-Guerin (BCG); Vaccine 19 (2000) 1294-1297.
(4 pages)
Cited by 2 patents
[ISI abstract]
Naito et al, The Antigen 85 Complex Vaccine Against Experimental Mycobacterium Leprae Infection in Mice; Vaccine 18 (2000), 795-798.
Ohara, et al.; Characterization of the Transcriptional Initiation Regions of Genes for the Major Secreted Protein Antigens 85C and MPB51 of Mycobacterium Bovis BCG.
Bacterial Vaccine Vectors and Bacillus Calmette-Guerin, Jeffrey D. Cirillo, et al., Clinical Infectious Diseases, 1995; 20: 1001-9.
(9 pages)
Cited by 6 patents
[ISI abstract]
New Use of BCG for Recombinant Vaccines, C.K. Stover, et al., Nature, vol. 351, Jun. 6, 1991.
Systemic and Mucosal Immunity Induced by BCG Vector Expressing Outer-Surface Protein A of Borrelia Burgdorferi, Solomon Langermann, et al., Nature, vol. 372, Dec. 8, 1994.
Protective Humoral Response Against Pneumococcal Infection in Mice Elicited by Recombinant Bacille Calmette-Guerin Vaccines Expressing Pneumococcal Surface Protein A, Solomon Langermann, et al., J. Exp. Med., The Rockefeller University Press, vol. 180, Dec. 1994, 2277-2286.
(10 pages)
Cited by 11 patents
[ISI abstract]
Protective Immunity Elicited by Recombinant Bacille Calmette-Guerin (BCG) Expressing Outer Surface Protein A (OspA) Lipoprotein: A Candidate Lyme Disease Vaccine, C. Kendall Stover, et al., J. Exp. Med., The Rockefeller University Press, vol. 178, Jul. 1993, 197-209.
(13 pages)
Cited by 11 patents
[ISI abstract]
Immunization with Recombinant BCG-SIV Elicits SIV-Specific Cytotoxic T Lymphocytes in Rhesus Monkeys, Yasuhiro Yasutomi, et al., The Journal of Immunology, vol. 150, 3101-3107, No. 7, Apr. 1, 1993.
(7 pages)
Cited by 2 patents
[ISI abstract]
Development and Analysis of Recombinant BCG Vector Systems, Thomas R. Fuerst, et al., AIDS Research and Human Retroviruses, vol. 8, No. 8, 1992.
Use of Recombinant BCG as a Vaccine Delivery Vehicle, C. Kendall Stover, et al., Advances in Experimental Medicine and Biology, vol. 327.
Protective Immunity Elicited by rBCG Vaccines, C. K. Stover, et al., Brown F(ed) Recombinant Vectors in Vaccine Development, Dev Biol Stand. Basel, Karger, 1994, vol. 82, pp 163-170.
Efficacy and Safety of Live Recombinant BCG Vaccines, M. S. Hanson, et al., Non-Target Effects of Live Vaccines, Dev Biol Stand. Basel, Karger, 1995, vol. 84, pp 229-236.
High-Level Heterologous Expression and Secretion in Rapidly Growing Nonpathogenic Mycobacteria of Four Major Mycobacterium Tuberculosis Extracellular Proteins Considered to be Leading Vaccine Candidates and Drug Targets, Gunter Harth, et al., Infection and Immunity, Jun. 1997, p. 2321-2328.
(8 pages)
Cited by 3 patents
[ISI abstract]
Novel Insights into the Genetics, Biochemistry, and Immunocytochemistry of the 30-Kilodalton Major Extracelluar Protein of Mycobacterium Tuberculosis, Gunter Harth, et al., Infection and Immunity, Aug. 1996, p. 3038-3047.
(10 pages)
Cited by 3 patents
[ISI abstract]
|
| Continuity Data: |
| Application Number | Filed | Notes |
|---|
|
|
US2000000550468 | 2000-04-17 | is a
related to the prior publication |
| |
US20040009184A1 issued 2004-01-15 Recombinant intracellular pathogen immunogenic compositions and methods for use
|
|
|
|
US2003000439611 | 2003-05-15 | is a
continuation in part of |
|
US2002000261981
| 2002-09-30 |
(abandoned)
|
| |
US20030124135A1 issued 2003-07-03 Recombinant intracellular pathogen vaccines and methods for use
|
|
|
|
US2003000439611 | | is a
continuation in part of |
|
US2002000261981
| 2002-09-30 |
(abandoned)
|
| |
US20030124135A1 issued 2003-07-03 Recombinant intracellular pathogen vaccines and methods for use
|
|
|
|
US2002000261981 | 2002-09-30 | is a
continuation in part of |
|
>US2000000550468<
| 2000-04-17 |
(granted)
|
| |
US6471967 issued 2002-10-29 Recombinant intracellular pathogen vaccines and methods for use
|
|
|
|
US2002000261981 | | is a
continuation in part of |
|
>US2000000550468<
| 2000-04-17 |
|
| |
US6471967 issued 2002-10-29 Recombinant intracellular pathogen vaccines and methods for use
|
|
|
|
 Nominate this for the Gallery...
|
|
